TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.
Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Hambelton GM, Pecci F, Makarem M, Gandhi MM, Garbo E, De Giglio A, Gagliano A, Sperandi F, Gelsomino F, Scalera S, Cipriani L, Marinelli D, Lamberti G, Shaverdian N, Haradon J, Nguyen T, Voligny E, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Rodig SJ, Pfaff K, Wang X, Rekhtman N, Sholl LM, Luo J, Johnson BE, Janne PA, Arvind R, Gainor JF, Maugeri-Saccà M, Ardizzoni A, Heist RS, Arbour KC, Schoenfeld AJ, Vokes NI, Awad MM.
Di Federico A, et al. Among authors: cipriani l.
J Thorac Oncol. 2026 Jul;21(7):103610. doi: 10.1016/j.jtho.2026.103610. Epub 2026 Feb 12.
J Thorac Oncol. 2026.
PMID: 41690367